Active, not recruitingPhase 3NCT06935409
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hansoh BioMedical R&D Company
- Intervention
- HS-20093(drug)
- Enrollment
- 117 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- Beijing Jishuitan Hospital affiliated to Capital Medical University, Beijing, China
- Peking University People's Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06935409 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502885Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer PatientsSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT07193550A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.